CTOs on the Move

EPICA.ai

www.epica.ai

 
EPICA is the AI company that gives companies unprecedented power for decision making by detecting patterns of behavior of audiences in real time.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.epica.ai
  • 609, Greenwich St
    New York, NY USA 10014
  • Phone: 650.200.1991

Executives

Name Title Contact Details

Similar Companies

HyperQuality

HyperQuality is an independent quality assurance firm that delivers ROI through: improved customer contacts which help retain and acquire customers, excellence in customer experience through unbiased monitoring and analysis of customer interactions, and improved employee satisfaction.

Stolt-Nielsen Transportation Group

Stolt-Nielsen Transportation Group is one of the largest and most sophisticated parcel tanker operators in the world. Through its modern fleet, global network of terminals, storage facilities and tank containers, SNTG offers a powerful range of

top brands inc

top brands inc is a Oshkosh, WI-based company in the Business Services sector.

Igm Consulting

Igm Consulting is a New Hartford, NY-based company in the Business Services sector.

Apellis Pharmaceuticals

Apellis Pharmaceuticals is a global biopharmaceutical company based in Waltham, Massachusetts. The company is focused on developing innovative therapies that target the complement system, a crucial part of the immune system. Apellis aims to create life-changing treatments for various debilitating diseases through its commitment to scientific research and patient care. The company has a diverse pipeline of products, including EMPAVELI, which is approved for treating paroxysmal nocturnal hemoglobinuria and is being investigated for other conditions. SYFOVRE is in development for geographic atrophy, along with a combination therapy involving APL-APL-3007. Apellis is also exploring RNA therapies and gene-edited treatments for multiple therapeutic areas. With a global presence in countries such as the US, Canada, and several European nations, Apellis serves patients and healthcare providers affected by diseases related to the complement system. The company reported approximately $709 million in U.S. net product revenues for the full year 2024, reflecting its strong market position and commitment to advancing its therapeutic offerings.